Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.42 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17676467 | 0.90 | ALDH1A1 (0.49) | KMT2APOLBGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL13490817 | 0.84 | CNR1 (0.51) | KMT2APOLBSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL30880758 | 0.83 | SMN1; SMN2 (0.43) | KMT2APOLBGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL10272935 | 0.78 | SMN1; SMN2 (0.62) | KMT2APOLBGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL13490812 | 0.78 | PPARA (0.49) | KMT2AGAASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL13490774 | 0.78 | SMN1; SMN2 (0.45) | KMT2APOLBSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL8838392 | 0.76 | L3MBTL1 (0.53) | KMT2APOLBHSD17B1HSD17B2HTT | |
| SCHEMBL88823 | 0.75 | ALDH1A1 (0.61) | KMT2APOLBALDH1A1MAPK1 | |
| SCHEMBL5393479 | 0.74 | LMNA (0.53) | SMN1; SMN2ALDH1A1MAPTLMNAHPGD | |
| SCHEMBL16479226 | 0.74 | ALDH1A1 (0.51) | KMT2AGAASMN1; SMN2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | REN, PAH, ACE | KMT2A 3027/4885POLB 3495/4885GAA 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.